ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Given Consensus Rating of “Moderate Buy” by Analysts

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) has been given an average rating of “Moderate Buy” by the eight ratings firms that are currently covering the stock, MarketBeat Ratings reports. Three research analysts have rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average 1-year price target among analysts that have issued a report on the stock in the last year is $107.3333.

Several brokerages have recently weighed in on ANIP. Weiss Ratings reaffirmed a “hold (c+)” rating on shares of ANI Pharmaceuticals in a research report on Monday. Wall Street Zen raised shares of ANI Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Saturday, May 9th. Finally, Zacks Research cut shares of ANI Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Thursday, May 14th.

Insider Transactions at ANI Pharmaceuticals

In related news, CEO Nikhil Lalwani sold 55,000 shares of the business’s stock in a transaction that occurred on Monday, May 11th. The shares were sold at an average price of $77.57, for a total transaction of $4,266,350.00. Following the completion of the transaction, the chief executive officer owned 349,889 shares in the company, valued at $27,140,889.73. The trade was a 13.58% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, SVP Thomas Andrew Rowland sold 459 shares of the business’s stock in a transaction that occurred on Tuesday, May 12th. The stock was sold at an average price of $79.21, for a total transaction of $36,357.39. Following the transaction, the senior vice president owned 38,271 shares of the company’s stock, valued at approximately $3,031,445.91. This trade represents a 1.19% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders have sold 81,638 shares of company stock worth $6,348,562. Insiders own 8.10% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the company. Advisors Asset Management Inc. acquired a new position in ANI Pharmaceuticals during the 1st quarter valued at approximately $28,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in ANI Pharmaceuticals by 4.5% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 10,993 shares of the specialty pharmaceutical company’s stock valued at $736,000 after purchasing an additional 470 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its stake in ANI Pharmaceuticals by 0.9% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 48,322 shares of the specialty pharmaceutical company’s stock valued at $3,235,000 after purchasing an additional 423 shares in the last quarter. Jane Street Group LLC acquired a new position in ANI Pharmaceuticals during the 1st quarter valued at approximately $2,706,000. Finally, Norges Bank acquired a new position in ANI Pharmaceuticals during the 2nd quarter valued at approximately $625,000. Institutional investors own 76.05% of the company’s stock.

ANI Pharmaceuticals Price Performance

ANI Pharmaceuticals stock opened at $79.20 on Friday. The stock has a market cap of $1.80 billion, a price-to-earnings ratio of 20.05 and a beta of 0.44. The company has a debt-to-equity ratio of 1.06, a current ratio of 3.12 and a quick ratio of 2.52. ANI Pharmaceuticals has a 1 year low of $59.61 and a 1 year high of $99.50. The firm has a 50-day moving average of $78.92 and a two-hundred day moving average of $79.38.

ANI Pharmaceuticals (NASDAQ:ANIP) last released its quarterly earnings data on Friday, May 8th. The specialty pharmaceutical company reported $2.05 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.28 by $0.77. ANI Pharmaceuticals had a net margin of 9.98% and a return on equity of 27.51%. The company had revenue of $237.46 million during the quarter, compared to analysts’ expectations of $207.63 million. During the same period in the previous year, the company earned $1.70 EPS. The firm’s quarterly revenue was up 20.5% on a year-over-year basis. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. On average, research analysts forecast that ANI Pharmaceuticals will post 7.96 earnings per share for the current year.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.